Atracurium besylate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

苯磺酸阿曲库铵是一种作用持续时间短的非去极化神经肌肉阻滞剂。与替代的非去极化神经肌肉阻滞剂相比，它没有显着的心血管作用，并且不依赖良好的肾功能来消除，因此具有临床优势。

Atracurium Besilate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent.(In Vitro):Atracurium besylate (10 μM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells.Atracurium besylate (10 μM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs.Atracurium besylate (2.4 μM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells.(In Vivo):Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice.Atracurium besylate (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats.

Atracurium besylate (10 μM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells.Atracurium besylate (10 μM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs.Atracurium besylate (2.4 μM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells. Cell Proliferation Assay Cell Line:glioblastoma stem (GSC) cells Concentration:3, 10, 20 μM Incubation Time:72 h Result:Increased the percentage of GFP-positive cells in a dose-dependent manner from 5.3% in DMSO to 15.4%, 81.1%, and 86.8% in 3 μM, 10 μM, and 20 μM, respectively.

Atracurium besylate (1, 5, 10, 20, 50 mg/kg; i.v.) induces bronchoconstriction in DBA/2 and SJL mice.Atracurium besylate (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats. Animal Model:5-12 weeks, 15-20 g male mice Dosage:1, 5, 10, 20, 50 mg/kg Administration:I.v.Result:Induced bronchoconstriction and Atracurium-induced airway hyperresponsiveness in DBA/2 mice was eliminated in a dose-dependent manner by pretreatment with atropine or pancuronium.Animal Model:290 ± 30 g Male Sprague±Dawley rats (60 mg/kg heat-killed Corynebacteriumparvum for i.v.)Dosage:4.8 mg/kg Administration:I.v.Result:Induced neuromuscular blockade in Corynebacteriumparvum-injected rats.

Atracurium Besylate | Atracurium Dibesylate

Others

Other Targets

nAChR

Neurological Disease

——

64228-81-5

1243.49

C65H82N2O18S2

>98% (HPLC)

DMSO : 50 mg/mL 40.21 mM

[O-]S(=O)(=O)c1ccccc1.COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.[O-]S(=O)(=O)c1ccccc1

benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate

(-20℃)

With Ice Pack

≥ 2 years